A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects.

Trial Profile

A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Baricitinib (Primary) ; Moxifloxacin
  • Indications Psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2013 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 22 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top